0.83
-0.0225(-2.65%)
Currency In USD
| Previous Close | 0.85 |
| Open | 0.82 |
| Day High | 0.87 |
| Day Low | 0.77 |
| 52-Week High | 10.62 |
| 52-Week Low | 0.77 |
| Volume | 4.7M |
| Average Volume | 5.21M |
| Market Cap | 96.47M |
| PE | -0.58 |
| EPS | -1.42 |
| Moving Average 50 Days | 6.31 |
| Moving Average 200 Days | 5.78 |
| Change | -0.02 |
If you invested $1000 in Applied Therapeutics, Inc. (APLT) since IPO date, it would be worth $88.2 as of December 26, 2024 at a share price of $0.829. Whereas If you bought $1000 worth of Applied Therapeutics, Inc. (APLT) shares 3 years ago, it would be worth $85.3 as of December 26, 2024 at a share price of $0.829.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
GlobeNewswire Inc.
Dec 20, 2024 12:00 PM GMT
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
GlobeNewswire Inc.
Nov 27, 2024 9:10 PM GMT
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) ha
Applied Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 12:00 PM GMT
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD